We studied diagnostic and treatment values of the blood levels of platelet activation markers PNA, PMA, PLyA, PAC-1, and CD62P in 30 patients with acute ischemic stroke (median NIHSS score 4 (2; 6)) before and after treatment as well as in comparison with the control group. The levels of these markers were measured by flow cytometry. In patients with acute ischemic stroke, the levels of PLyA, PAC-1, and CD62P were significantly increased in comparison with the controls; therapy significantly reduced the levels of PAC-1, CD62P, and PMA in patients with acute ischemic stroke. The areas under the ROC curve differentiating acute ischemic stroke from healthy controls for PAC-1, CD62P, and PLyA were 0.694, 0.862, and 0.760, respectively. Our findings suggest that the levels of PLyA, PAC-1, and CD62P can be potential noninvasive biomarkers of acute ischemic stroke.
Keywords: biomarkers; diagnosis; ischemic stroke; platelet activation.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.